Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 10/20 | 0.53 |
| ▸ | PDGFRA | P16234 | 9/20 | 0.53 |
| ▸ | AXL | P30530 | 4/20 | 0.52 |
| ▸ | KIT | P10721 | 2/20 | 0.52 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.51 |
| ▸ | CSF1R | P07333 | 1/20 | 0.50 |
| ▸ | MET | P08581 | 3/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | MERTK | Q12866 | 3/20 | 0.48 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.48 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.48 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.48 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.48 |
| ▸ | LCK | P06239 | 1/20 | 0.48 |
| ▸ | PGR | P06401 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2175628 | 0.87 | MET (0.50) | KDRPDGFRAAXLKITFGFR2 | |
| SCHEMBL5598508 | 0.84 | CCNC (0.48) | KDRPDGFRAAXLKITFGFR2 | |
| SCHEMBL2172121 | 0.81 | PDGFRB (0.71) | KDRPDGFRAAXLKITFGFR2 | |
| SCHEMBL2176270 | 0.80 | PDGFRB (0.66) | KDRPDGFRAAXLKITFGFR2 | |
| SCHEMBL2173726 | 0.79 | KDR (0.73) | KDRPDGFRAAXLKITFGFR2 | |
| SCHEMBL4710074 | 0.78 | KDR (0.46) | KDRPDGFRAAXLKITFGFR2 | |
| SCHEMBL19182904 | 0.76 | PTGS2 (0.49) | — | |
| SCHEMBL31170887 | 0.76 | PTGS2 (0.49) | — | |
| SCHEMBL11727493 | 0.75 | GAK (0.61) | KDRPDGFRAAXLKITFGFR2 | |
| SCHEMBL4514154 | 0.75 | KDR (0.52) | KDRPDGFRAAXLKITFGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973164-B2 | Quinoline derivatives | ASTRAZENECA AB (SE) | 2011-07-05 | — | — | US | disclosed |
| US-20090076074-A1 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
| EP-1994025-A1 | QUINOLINE DERIVATIVES | AstraZeneca AB (SE) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007099326-A1 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076074-A1 | QUINOLINE DERIVATIVES | RECQL, NQO2, CCNA1 | KDR 2277/4885PDGFRA 1432/4885AXL 3664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.